Meeting
2014 Genitourinary Cancers Symposium
Using radiologic response to predict prognosis in patients with muscle-invasive bladder cancer undergoing carboplatin-based neoadjuvant chemotherapy.
Authors
Shingo Hatakeyama
Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan
Shingo Hatakeyama , Hayato Yamamoto , Akiko Okamoto , Atsushi Imai , Takahiro Yoneyama , Yasuhiro Hashimoto , Takuya Koie , Chikara Ohyama
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session B: Prostate, Penile, Urethral, and Testicular Cancers, and Urothelial Carcinoma
Track
Urothelial Carcinoma,Prostate Cancer,Penile, Urethral, and Testicular Cancers
Sub Track
Urothelial Carcinoma
Citation
J Clin Oncol 32, 2014 (suppl 4; abstr 361)
DOI
10.1200/jco.2014.32.4_suppl.361
Abstract #
361
Poster Bd #
K11
Abstract Disclosures
Similar Posters
Poster
2016 Genitourinary Cancers Symposium
Neoadjuvant gemcitabine and carboplatin followed by immediate radical cystectomy for muscle-invasive bladder cancer patients ineligible for cisplatin-based chemotherapy: A propensity score-matched analysis.
First Author: Takuya Koie
Poster
2023 ASCO Genitourinary Cancers Symposium
Radical radiotherapy for muscle-invasive bladder cancer: A single centre experience.
First Author: Mayumi Forster
Poster
2023 ASCO Genitourinary Cancers Symposium
FDG PET-CT imaging in assessing interim response to neoadjuvant cisplatin-based chemotherapy (NAC) in muscle invasive bladder cancer (MIBC): A prospective study.
First Author: Srikala S. Sridhar
Poster
2023 ASCO Genitourinary Cancers Symposium
Phase 2 open label study of durvalumab with neoadjuvant chemotherapy in variant histology bladder cancer.
First Author: Ali Raza Khaki